Advertisement

Evaluation of right ventricular pacing parameters in patients with proliferative scar

  • Veysel Kutay Vurgun
  • Emir Baskovski
  • Huseyin Goksuluk
  • Nil Ozyuncu
  • Turkan Seda Tan
  • Ali Timucin Altin
  • Basar Candemir
  • Omer Akyurek
Article
  • 76 Downloads

Abstract

Background

Dermal and myocardial injury results in a healing process, characterized by inflammation and fibrosis. We aimed to investigate association between proliferative scarring at the operation site and right ventricular (RV) pacing and sensing parameters, two clinical outcomes associated with impaired dermal and myocardial healing, respectively.

Methods

We performed an observational retrospective study among regularly followed pacemaker (PM)/implantable cardioverter defibrillator (ICD)-implanted patients at our medical center. Patients, who had a first RV active fixation PM/ICD lead implantation procedure and a minimum follow-up of 1 year, were included in the study. Redo procedures, passive fixation RV leads, epicardial leads, generator replacement procedures, and patients using class I and III anti-arrhythmic drugs were excluded. Patients in the control group, matched by age, sex and implanted device and lead type, were randomly selected from the patient pool. Lead impedance, pacing threshold, and R wave measurements obtained at baseline and at 3rd, 6th, and 12th month were analyzed.

Results

Baseline characteristics of study and control groups were similar. While baseline and follow-up lead impedance and R wave measurements along with baseline and 3rd-month pacing thresholds showed no significant difference between two groups, 6th- and 12th-month pacing thresholds revealed statistically significant increase in proliferative scar group compared to control group (0.87 vs 0.72 p = 0.003 and 0.87 vs 0.71 p = 0.003, respectively).

Conclusions

PM/ICD-implanted patients with proliferative scar on pocket wound may show increased RV pacing thresholds compared to patients with normal healing of pocket wound.

Keywords

Active fixation lead Implantable cardioverter defibrillator Proliferative scar Pacemaker Pacing threshold 

Notes

Acknowledgments

The authors would like to thank Senay Simsek for her assistance to the follow-up of the patients.

Author contributions

V.K.V. and H.G. designed this study. V.K.V., E.B., H.G., N.O., and T.S.T.K. collected and analyzed the data. O.A., A.T.A., and B.C. interpreted results of the study. V.K.V., E.B., and H.G. did statistical analyses, prepared figures, and wrote the paper. All authors edited and revised manuscript and approved final submission of manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethical Committee on Human Research in Ankara University School of Medicine (App No: 05-231-17).

References

  1. 1.
    Hu Z-C, Tang B, Guo D, Zhang J, Liang Y-Y, Ma D, et al. Expression of insulin-like growth factor-1 receptor in keloid and hypertrophic scar. Clin Exp Dermatol. 2014;39:822–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Heart E, Association R, Task A, Members F, Brignole M, Bordachar P, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2013;34:2281–329.CrossRefGoogle Scholar
  3. 3.
    Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36:2793–867.CrossRefGoogle Scholar
  4. 4.
    Czubryt MP. Common threads in cardiac fibrosis, infarct scar formation, and wound healing. Fibrogenesis Tissue Repair. 2012;5:1–11.CrossRefGoogle Scholar
  5. 5.
    Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31:224–30.CrossRefPubMedGoogle Scholar
  6. 6.
    Ghahary A, Shen YJ, Scott PG, Tredget EE. Immunolocalization of TGF-beta 1 in human hypertrophic scar and normal dermal tissues. Cytokine. 1995;7:184–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Nikol S, Isner JM, Pickering JG, Kearney M, Leclerc G, Weir L. Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. J Clin Invest. 1992;90:1582–92.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sullivan T, Smith J, Kermode J, McIver E, Courtemanche DJ. Rating the burn scar. J Burn Care Rehabil. 1990;11:256–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Nedelec B, Shankowsky HA, Tredget EE. Rating the resolving hypertrophic scar: comparison of the Vancouver Scar Scale and scar volume. J Burn Care Rehabil. 2000;21:205–12.CrossRefPubMedGoogle Scholar
  10. 10.
    Thompson CM, Sood RF, Honari S, Carrougher GJ, Gibran NS. What score on the Vancouver Scar Scale constitutes a hypertrophic scar? Results from a survey of North American burn-care providers. Burns. 2015;41:1442–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dohrmann ML, Goldschlager NF. Myocardial stimulation threshold in patients with cardiac pacemakers: effect of physiologic variables, pharmacologic agents, and lead electrodes. Cardiol Clin. 1985;3:527–37.CrossRefPubMedGoogle Scholar
  12. 12.
    Dvorak P, Novak M, Kamaryt P, Slana B, Lipoldova J, Dvorak P. Histological findings around electrodes in pacemaker and implantable cardioverter-defibrillator patients: comparison of steroid-eluting and non-steroid-eluting electrodes. Europace. 2012;14:117–23.CrossRefPubMedGoogle Scholar
  13. 13.
    Mond HG, Stokes KB. The electrode-tissue interface: the revolutionary role of steroid elution. Pacing Clin Electrophysiol. 1992;15:95–107.CrossRefPubMedGoogle Scholar
  14. 14.
    Radovsky AS, Van Vleet JF, Stokes KB, Tacker WA. Paired comparisons of steroid-eluting and nonsteroid endocardial pacemaker leads in dogs: electrical performance and morphologic alterations. Pacing Clin Electrophysiol. 1988;11:1085–94.CrossRefPubMedGoogle Scholar
  15. 15.
    Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011;17:113–25.CrossRefPubMedGoogle Scholar
  16. 16.
    Ogawa R, Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis—keloids and hypertrophic scars may be vascular disorders. Med Hypotheses. 2016;96:51–60.CrossRefPubMedGoogle Scholar
  17. 17.
    Ozdol C, Turhan S, Tulunay C, Altin AT, Atmaca Y, Candemir B, et al. Association between proliferative scars and in-stent restenosis. J Cutan Med Surg. 2007;11:206–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Ziyrek M, Sahin S, Acar Z, Sen O. The relationship between proliferative scars and endothelial function in surgically revascularized patients. Balkan Med J. 2015;32:377–81.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Pivatto Júnior F, Chemello D, Mazzutti G, Pimentel M, Rabaioli P, Zimerman L. Early improvement of pacing threshold following primary right coronary angioplasty. Heart Rhythm Case Rep. 2017;3:90–2.CrossRefGoogle Scholar
  20. 20.
    Murray JC. Keloids and hypertrophic scars. Clin Dermatol. 1994;12:27–37.CrossRefPubMedGoogle Scholar
  21. 21.
    Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014;100:153–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Enoshiri T, Naitoh M, Yamawaki S, Kawaguchi A, Aya R, Noda K, et al. β-Adrenergic receptor blockers reduce the occurrence of keloids and hypertrophic scars after cardiac device implantation: a single-institution case-control study. Plast Reconstr Surg. 2017;139:1248–56.CrossRefPubMedGoogle Scholar
  23. 23.
    Wiggins NB, Chong DT, Houghtaling PL, Hussein AA, Saliba W, Sabik JF, et al. Incidence, indications, risk factors, and survival of patients undergoing cardiac implantable electronic device implantation after open heart surgery. Europace. 2017;19:1335–42.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Cardiology DepartmentAnkara University School of MedicineMamakTurkey

Personalised recommendations